AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04239352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein-associated phospholipase A2 ; new biomarker
Description: Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
Study NCT03369626 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FareWell Program
Description: The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
Study NCT01942811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Using Drugs Intervention Trial
Description: The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
Study NCT02869893 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Secretin
Study NCT02036684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation (PREHAB)
Study NCT03076515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio Migra neurostimulation
Description: transcutaneous electrical stimulation
Study NCT03076515 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nerivio Migra
Description: electrical stimulation- shame mode
Study NCT00057525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax
Description: Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
Study NCT00057525 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alhdryogel or PBS
Description: Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
Study NCT03942887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
Study NCT03942887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endoxan
Description: Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
Study NCT03942887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
Study NCT03942887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
Study NCT03070275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece
Description: Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
Study NCT03070275 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage surgical implant placement
Description: Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
Study NCT03029455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659
Study NCT03029455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor
Study NCT03029455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT03029455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659 Matching Placebo
Study NCT03029455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Combination (TC) Matching Placebos
Study NCT00329745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral administration, 2 doses
Study NCT00329745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, 2 doses
Study NCT00212264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Pelvic Floor Muscle Exercises and Bladder control strategies
Study NCT00212264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Electrical Stimulation
Description: Pelvic Floor Electrical Stimulation daily for 8 weeks
Study NCT04527484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR-1314
Description: each group subjects will be given different formulations of SHR-1314
Study NCT00212264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Pelvic Floor Muscle training via biofeedback
Study NCT00212264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment
Description: No treatment
Study NCT04582201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agenT-797
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study NCT02486172 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer support program
Description: Peer support program as an additional service to the routine clinical service
Study NCT02370056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3-dimensional visualization
Description: Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
Study NCT02370056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2-dimensional visualization
Description: Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
Study NCT00953615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Titrate to 400 mg daily for 6 months
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB007
Description: the study drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: asthma-controlled drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Symbicort
Description: asthma-controlled drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: asthma-controlled drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seretide
Description: asthma-controlled drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin
Description: asthma rescue drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ventolin
Description: asthma rescue drug
Study NCT03468790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No active components
Study NCT04278170 — intervention group
Intervention type: OTHER
Intervention: no attempt was made to patients
Description: no attempt was made to patients
Study NCT04038164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog-Assisted Therapy and pharmacological treatment
Description: The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
Study NCT04038164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog-Assisted Therapy and pharmacological treatment
Description: The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
Study NCT02320448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Study NCT01734057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO); rituximab
Description: patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)
Study NCT01734057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Study NCT03339557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen
Description: Comparing two conventional designs and one novel design
Study NCT03339557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona
Description: Comparing two conventional designs and one novel design
Study NCT03339557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC
Description: Comparing two conventional designs and one novel design
Study NCT01266005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg,QD
Study NCT01266005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg QD
Study NCT00551525 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
Study NCT00551525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium 153
Description: Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
Study NCT01308892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol chocolate
Description: chocolate high in flavanols
Study NCT01308892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol chocolate
Description: chocolate low in flavanols
Study NCT01308892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat challenge
Description: Milkshake with 95g fat
Study NCT01308892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High fat challenge
Description: Milkshake with 95g fat
Study NCT04012177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced-energy protein (BEP)
Description: Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
Study NCT04012177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
Study NCT04012177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Bitartrate
Description: Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
Study NCT04012177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
Study NCT03113318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mediastinal lymph node dissection and pulmonary metastasectomy
Description: Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
Study NCT03113318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only pulmonary metastasectomy
Study NCT01110408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
Study NCT01110408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
Study NCT01110408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
Study NCT01110408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
Study NCT01110408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
Study NCT05505695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brace and Exercise Treatment
Description: Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
Study NCT05505695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace Treatment
Description: Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
Study NCT05141929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based education
Description: In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
Study NCT03990311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Restricted Meals
Description: 2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
Study NCT03990311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual Care
Study NCT02078596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
Study NCT02078596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
Study NCT02847910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the disposable tissue suction set
Description: Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
Study NCT02847910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional metal instruments of abortion
Description: Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
Study NCT02927353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-3113
Description: subcutaneously injected in a single dose of 40 mg.
Study NCT02927353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: subcutaneously injected in a single dose of 40 mg.
Study NCT04442152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MenCare+/Bandebereho fathers'/couples' group education
Description: MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
Study NCT00877539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03526299
Description: Inhaled, two doses 4 hours apart
Study NCT00877539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled, two doses 4 hours apart
Study NCT00877539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled
Study NCT00657657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
Study NCT02211664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 balloon
Study NCT02211664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug releasing balloon
Study NCT02211664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsar-18 stent
Study NCT02548663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sport therapy
Description: Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises.
Study NCT02548663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: Frequency: 60 min weekly
Study NCT02080364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Azeliragon 5mg administered orally, once daily for 18 months
Study NCT02080364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, once daily for 18 months
Study NCT02787681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEMO Gauge
Description: Measurement and adjustment of endotracheal tube position by stylet.
Study NCT02058589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT02058589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT01613144 — intervention group
Intervention type: DEVICE
Intervention: OsseoScrew Spinal Fixation System
Description: Surgical intervention
Study NCT00770744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zicronapine
Description: 5-7mg/day; orally, encapsulated tablets, once daily
Study NCT03585972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frailty Prevention Program
Description: 4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.